DIAGNOSTIC ADVANCES

11 Nonalcoholic fatty liver disease: Diagnostic biomarkers
Hadizadeh F, Faghihimani E, Adibi P

REVIEW

27 Celiac disease: From pathophysiology to treatment
Parzanese I, Qehajaj D, Patrinicola F, Aralica M, Chiriva-Internati M, Stifter S, Elli L, Grizzi F

39 Embrionary way to create a fatty liver in portal hypertension
Aller MA, Arias N, Peral I, Garcia-Higarza S, Arias JL, Arias J

MINIREVIEWS

51 Non-alcoholic fatty liver disease and cardiovascular risk
Patil R, Sood GK

ORIGINAL ARTICLE

Basic Study

59 Rectification of oxygen transfer through the rat colonic epithelium
Saraví FD, Carra GE, Matus DA, Ibáñez JE

67 Combination curcumin and vitamin E treatment attenuates diet-induced steatosis in Hfe<sup>−/−</sup> mice
Heritage M, Jaskowski L, Bridle K, Campbell C, Briskey D, Britton I, Fletcher L, Vietta L, Subramaniam VN, Crawford D

Observational Study

77 Endoscopic therapy for biliary strictures complicating living donor liver transplantation: Factors predicting better outcome
Harshavardhan RB, Ahamed H, Panicker S, Sudhindran S, Venu RP

CASE REPORT

87 Differential diagnosis in ulcerative colitis in an adolescent: Chronic granulomatous disease needs extra attention
Kotlarz D, Egritas Gurkan O, Haskologlu ZS, Ekinci O, Aksu Unlusoy A, Gürcan Kaya N, Puchalka J, Klein C, Dalgic B

93 Duodenal localization of plasmablastic myeloma
Licci S

96 Late onset pulmonary metastasis more than 10 years after primary sigmoid carcinoma
Daniels AM, Vogelaar JFJ
World Journal of Gastrointestinal Pathophysiology
Volume 8 Number 2 May 15, 2017

ABOUT COVER
Editorial Board Member of World Journal of Gastrointestinal Pathophysiology, Zhao-Xiang Bian, PhD, Professor, Director of Clinical Division, School of Chinese Medicine, Baptist University, Hong Kong, China

AIM AND SCOPE
World Journal of Gastrointestinal Pathophysiology (World J Gastrointest Pathophysiol, WJGP, online ISSN 2150-5330, DOI: 10.4291), is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJGP is to report rapidly the most recent results in basic and clinical research on gastrointestinal pathophysiology, including all aspects of normal or abnormal function of the gastrointestinal tract, hepatobiliary system, and pancreas. WJGP specifically covers growth and development, digestion, secretion, absorption, metabolism and motility relative to the gastrointestinal organs, as well as immune and inflammatory processes, and neural, endocrine and circulatory control mechanisms that affect these organs. This journal will also report new methods and techniques in gastrointestinal pathophysiological research.

We encourage authors to submit their manuscripts to WJGP. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

INDEXING/ABSTRACTING
World Journal of Gastrointestinal Pathophysiology is now indexed in PubMed, PubMed Central.

FLYLEAF
I-IV  Editorial Board

EDITORIAL OFFICE
Xiu-Xia Song, Director
World Journal of Gastrointestinal Pathophysiology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com

PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com

PUBLICATION DATE
May 15, 2017

COPYRIGHT
© 2017 Baishideng Publishing Group Inc. Articles published by this Open Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
http://www.wjgnet.com/bpg/gerinfo/204

ONLINE SUBMISSION
http://www.f6publishing.com
Late onset pulmonary metastasis more than 10 years after primary sigmoid carcinoma

Anne M Daniels, Jeroen F J Vogelaar

Anne M Daniels, Jeroen F J Vogelaar, Department of Surgery, VieCuri Medical Centre, 5912 BL Venlo, The Netherlands

Author contributions: Daniels AM was responsible for sample collection, acquisition of patient data, drafting and revising of the manuscript; Vogelaar JFJ planned the study and revised the manuscript.

Institutional review board statement: Approval from the Local Ethical Committee for this study was granted.

Informed consent statement: Informed consent was obtained from the patient.

Conflict-of-interest statement: Both authors have no conflicts of interests to declare.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Correspondence to: Anne M Daniels, BSc, Department of Surgery, VieCuri Medical Centre, Tegelseweg 210, 5912 BL Venlo, The Netherlands. amandaniels1991@gmail.com
Telephone: +31-77-320555
Fax: +31-77-325309

Received: October 25, 2016
Peer-review started: October 27, 2016
First decision: December 1, 2016
Revised: January 3, 2017
Accepted: March 12, 2017
Article in press: March 13, 2017
Published online: May 15, 2017

Abstract

According to current guidelines, follow-up of patients with colorectal cancer is ended after five years. Also, chest X-ray is not part of standard investigation during follow-up. We describe a case of a 74-year-old patient, more than ten years after a sigmoid resection because of carcinoma of the sigmoid. No recurrence was detected during intensive follow-up. However, ten years after resection of the sigmoid adenocarcinoma, complaints of coughing induced further examination with as result the detection of a solitary metastasis in the left lung of the patient. Within half-a-year after metastasectomy of the lung metastasis, she presented herself with thoracic pain and dyspnea resulting in discovering diffuse metastasis on pulmonary, pleural, costal and muscular level. Five year follow-up of colorectal carcinoma without chest X-ray can be questioned to be efficient. The growing knowledge of tumor biology might in future adjust the duration and frequency of diagnostic follow-up to prevent (late) recurrence in patients with colorectal carcinoma.

Key words: Colorectal cancer; Metastasis; Tumor biology; Tumor dormancy; Follow-up

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: This case report presents a case of a woman with pulmonary metastases 10 years after a sigmoid resection. No recurrence of the primary intestinal tumor was detected during follow-up. Upcoming knowledge on tumor behavior based on its biology might give new insights in late-onset metastases. Therefore, follow-up protocols and current therapy guidelines might have to be re-evaluated.

Daniels AM, Vogelaar JFJ. Late onset pulmonary metastasis more than 10 years after primary sigmoid carcinoma. World J Gastrointest Pathophysiol. 2017; 8(2): 96-99 Available from: URL: http://www.wjgnet.com/2150-5330/full/v8/i2/96.htm DOI: http://dx.doi.org/10.4291/wjgp.v8.i2.96
INTRODUCTION

Colorectal carcinoma (CRC) is the most common type of gastrointestinal cancer. The current screening methods enable early detection, for example adenomatous polyps, to prevent the development of invasive carcinoma[1]. Etiology of CRC comprises genetic involvement, molecular events, environmental factors and inflammatory conditions[2]. CRC usually develops over a period of 10-15 years[3], most often affecting people aged over 50[4]. After a curative resection, prognosis of CRC is worse in poorly differentiated, mucinous carcinomas with large invasion depth and in the presence of lymph node metastases[5]. Follow-up of patients with CRC according to the national guidelines consists of echography or computed tomography (CT) of the abdomen, colonoscopy and determination of carcinoembryonic antigen (CEA) until five years after surgical resection[6]

CRC can spread by lymphatic and hematogenous dissemination, as well as by contiguous and transperitoneal routes. Metastasis, at initially diagnosis present in 20% of all patients, is the main cause of mortality in patients with CRC[7,8]. When cancer spreads to one single organ, the malignancy presents itself with a specific biological profile and clinical characteristics. The site of the metastatic disease influences the prognosis and the possibilities for treatment. Organs most often affected by CRC are the liver and the lungs[9]. For pulmonary lesions, the criteria for resectability of the metastatic lesion comprise; control of the primary tumor; possible complete resection and adequate pulmonary reserve to tolerate the planned resection[10].

CASE REPORT

Ten years ago, a 63-year-old woman was admitted to our hospital with changes in bowel habits. At that time, she had no medical history of abdominal complaints or surgical operations. Her father was familiar with lung carcinoma, her mother and both of her sisters suffered from breast carcinoma.

A colonoscopy reveals a sigmoid colon stricture with unknown length due to the impossibility of endoscopically passing the stricture. Biopsy of the sigmoid shows a poorly differentiated adenocarcinoma. Computed tomography and echography of the liver, spleen and of the pelvic, cardio-thoracic, para-aortic and paracaval region show no lesions suspected for malignancy. An uncomplicated surgical resection of the sigmoid took place. The tumor, with a maximum diameter of five centimeters, including five surrounding lymph nodes and infiltrated fat tissue were removed in totality. No lymph node metastases were detected.

One year after the surgical resection, biopsy of a polyp of the ascending colon showed a tubular adenoma with low grade dysplasia. During further follow up of this patients no malignancies or recurrent lesions were disclosed. The CEA was tested every three months with a maximum value of 2.2 mcg/L. The intensive follow-up period was completed five years after sigmoid resection.

Ten years after resection of the adenocarcinoma located in the sigmoid without recurrent carcinoma’s during follow up, our patient presented herself with persistent coughing. Imaging of the thorax shows a lesion of 1.5 centimeters located in the inferior lobe of the left lung (Figure 1). Biopsy reveals an adenocarcinoma with positive CDX-2 staining, corresponding with intestinal origin of the cells. The pulmonary tumor was removed by video assisted thoracic surgery (VATS), presumably in totality. Colonoscopy shows no metachronous neoplasia. Within half a year, she was admitted to our emergency department with complaints of pain on the left side of her chest resulting in dyspnea, the pain was coherent with breathing movement and pain radiation towards her spine. CT-thorax shows extensive pleural, costal and muscular metastases (Figure 2). To reduce pain, palliative chemotherapy and additional radiotherapy were started.

DISCUSSION

Early detection of relapse or metastatic disease can be effectuated by intensive follow up during five years as recorded in the directive of Oncoline[9]. This follow-up comprises echography and optional CT-abdomen twice a year during 1-2 years, followed by once a year up to 5 years after the surgical resection. CEA should be determined every 3-6 mo during 3 years, followed by every 6 mo until 5 years after treatment. Colonoscopy is performed three, six and twelve months after surgical resection. Based on the number, localization and size of the lesions, repetition of colonoscopy is indicated after 3 or 5 years[6].

However, several clinical and experimental observations suggest that metastases can develop even in the absence of a detectable primary tumor. Both large and small tumors have the capability to metastasize[11,12]. Dissemination of tumor cells can occur in pre-invasive stages of tumor progression resulting in the development of early dormant disseminated tumor cells (DTCs). Early DTCs can remain dormant for a long period with...
manifestation of metastatic growth as result\textsuperscript{13,14}. Metastases may thus be initiated by and evolve from dormant DTCs, rather than established primary tumors. These DTCs can generate metastases with different characteristics from those of the primary tumor. The discriminating characteristics may explain the lack of success treating metastases with therapies based on primary tumor characteristics\textsuperscript{14}. Clinical evidence supports that the vast majority of early DTCs seem to be dormant\textsuperscript{12}.

In conclusion, five year follow-up of colorectal carcinoma without chest X-ray can be questioned to be efficient with the upcoming knowledge of early DTCs. Adjustment of the duration and frequency of diagnostic follow-up and adjustment of treatment might be effective for early detection of metastatic disease and prevention of late recurrence in patients with colorectal carcinoma.

ACKNOWLEDGMENTS

The authors wish to thank Simons P, MD, PhD for providing the CT-scan figures.

REFERENCES

1 Desch CE, Benson AB, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Pfister DG, Virgo KS, Petrelli NJ. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005; 23: 8512-8519 [PMID: 16260687 DOI: 10.1198/1078-0432.CCR-05-04063]
2 Dragovich T, Tsihrintzis VA, Talavera F, Espat NJ, Schulman P. Colon Cancer. Medscape 2016 Available from: URL: http://emedicine.medscape.com/article/277496-overview
3 Kelloff GJ, Schilsky RL, Alberts DS, Day RW, Guyton KZ, Pearce HL, Peck JC, Phillips R, Sigman CC. Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs. Cln Cancer Res 2004; 10: 3908-3918 [PMID: 15173100 DOI: 10.1158/1078-0432.CCR-03-0789]
4 Howlader N, Noone AM, Krapcho M, Gakhan J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Stomach V, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012. National Cancer Institute. Bethesda, MD, United States. Available from: URL: http://seer.cancer.gov/csr/1975_2012/
5 Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and Cotran Pathologic Basis of Disease, Professional Edition: Elsevier Health Sciences; 2014
6 Comprehensive Cancer Centre The Netherlands. Dutch guideline “colorectal carcinoma”. 2016
7 Van Cutsem E, Oliveira J. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 Suppl 4: 61-63 [PMID: 19454465 DOI: 10.1093/annonc/mdp130]
8 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66(1):7-30 [PMID: 26991315 DOI: 10.3322/caac.21332]
Daniels AM et al. A rare disease course

J Clin 2016; 66: 7-30 [PMID: 26742998]

9 Vatandoust S, Price TJ, Karapetis CS. Colorectal cancer: Metastases to a single organ. World J Gastroenterol 2015; 21: 11767-11776 [PMID: 26557001 DOI: 10.3748/WJG.v21.i41.11767]

10 Warwick R, Page R. Resection of pulmonary metastases from colorectal carcinoma. Eur J Surg Oncol 2007; 33 Suppl 2: S59-S63 [PMID: 18023132 DOI: 10.1016/j.ejso.2007.09.018]

11 van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 2002; 38: 409-413 [PMID: 11818207 DOI: 10.1016/S0959-8049(01)00378-1]

12 Engel J, Eckel R, Kerr J, Schmidt M, Fürstenberger G, Richter R, Sauer H, Senn HJ, Hölzel D. The process of metastasisation for breast cancer. Eur J Cancer 2003; 39: 1794-1806 [PMID: 12888376 DOI: 10.1016/S0959-8049(03)00422-2]

13 Hüsemann V, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riehmüller G, Klein CA. Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13: 58-68 [PMID: 18167340 DOI: 10.1016/j.ccr.2007.12.003]

14 Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer 2014; 14: 611-622 [PMID: 25118602 DOI: 10.1038/nrc3793]

P- Reviewer: Akiho H, Deng CX, Peinado MA  S- Editor: Gong ZM  L- Editor: A  E- Editor: Wu HL
